Crescent Biopharma, Inc. (CBIO)

Crescent Biopharma, Inc. (CBIO) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $532M; returns 1 day -2.4%, 1 week +8.3%, 1 year +0.2%.

Crescent Biopharma, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for the treatment of solid tumors. Founded through a reverse merger with GlycoMimetics in June 2025, Crescent's lead asset is CR-001, a tetravalent bispecific antibody targeting anti-programmed cell death-1 (PD-1) and vascular endothelial growth factor (VEGF).

Groups CBIO belongs to

• Clinical Stage Biotech
• Healthcare
• Biotechnology
• Biopharmaceutical
• Oncology
• Cancer Therapeutics
• Clinical Stage
• Clinical Stage Biopharma
• Antibody-Drug Conjugates
• Bispecific Antibodies
• Immunotherapy
• Antibody Therapeutics
• Monoclonal Antibodies
• PD-L1

CBIO financial model: income statement, cash flow and balance sheet